Present day controversies and consensus in curettage for giant cell tumor of bone.
Bone tumors
Curettage
Denosumab
Giant cell tumor
Surgery
Journal
Journal of clinical orthopaedics and trauma
ISSN: 0976-5662
Titre abrégé: J Clin Orthop Trauma
Pays: India
ID NLM: 101559469
Informations de publication
Date de publication:
Historique:
received:
06
07
2019
revised:
23
09
2019
accepted:
24
09
2019
entrez:
19
11
2019
pubmed:
19
11
2019
medline:
19
11
2019
Statut:
ppublish
Résumé
The ideal treatment for giant cell tumor of bone (GCTB) is still controversial. The purpose of this study was to evaluate whether curettage was successful in the treatment of GCTB. Intralesional curettage with adjuvant therapies, such as high-speed burring, polymethylmethacrylate, phenol, ethanol, and liquid nitrogen, may be used to reduce the local recurrence rate. However, there is no consensus on the optimal use of curettage, along with fillers and adjuvants, to limit the recurrence rate. We performed a systematic review of articles using the terms long bones, GCTB, and treatment. Case reports, reviews, opinion articles, or technique notes were excluded based on the abstract. Twenty-six articles included in this review were then studied to establish the index in suggesting the surgical treatment of GCTB. The patient's gender, their age, the Campanacci grade of their tumor, and the type of surgery they had were not significantly associated with the local recurrence rate. Local recurrences seemed to be associated with the site of the tumor, occurring more frequently in the proximal femur or distal radius. A pathological fracture was not a contraindication for intralesional curettage. Treatment with denosumab did not decrease the local recurrence rate in patients who had been treated with curettage. The current literature seems to suggest that the ideal treatment for GCTB is to remove the tumor while preserving as much of the joint as possible. Local recurrent tumors can be treated with curettage to keep the re-recurrence rate within an acceptable limit. The choice for how to treat GCTB in the proximal femur or distal radius requires special attention.
Sections du résumé
BACKGROUND
BACKGROUND
The ideal treatment for giant cell tumor of bone (GCTB) is still controversial. The purpose of this study was to evaluate whether curettage was successful in the treatment of GCTB. Intralesional curettage with adjuvant therapies, such as high-speed burring, polymethylmethacrylate, phenol, ethanol, and liquid nitrogen, may be used to reduce the local recurrence rate. However, there is no consensus on the optimal use of curettage, along with fillers and adjuvants, to limit the recurrence rate.
METHODS
METHODS
We performed a systematic review of articles using the terms long bones, GCTB, and treatment. Case reports, reviews, opinion articles, or technique notes were excluded based on the abstract. Twenty-six articles included in this review were then studied to establish the index in suggesting the surgical treatment of GCTB.
RESULTS
RESULTS
The patient's gender, their age, the Campanacci grade of their tumor, and the type of surgery they had were not significantly associated with the local recurrence rate. Local recurrences seemed to be associated with the site of the tumor, occurring more frequently in the proximal femur or distal radius. A pathological fracture was not a contraindication for intralesional curettage. Treatment with denosumab did not decrease the local recurrence rate in patients who had been treated with curettage.
CONCLUSION
CONCLUSIONS
The current literature seems to suggest that the ideal treatment for GCTB is to remove the tumor while preserving as much of the joint as possible. Local recurrent tumors can be treated with curettage to keep the re-recurrence rate within an acceptable limit. The choice for how to treat GCTB in the proximal femur or distal radius requires special attention.
Identifiants
pubmed: 31736607
doi: 10.1016/j.jcot.2019.09.017
pii: S0976-5662(19)30496-5
pmc: PMC6844202
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1015-1020Informations de copyright
© 2019 Delhi Orthopedic Association. All rights reserved.
Déclaration de conflit d'intérêts
All authors have not conflict of interest.
Références
Clin Orthop Relat Res. 2002 Apr;(397):248-58
pubmed: 11953616
J Cancer Res Clin Oncol. 2009 Jan;135(1):149-58
pubmed: 18521629
HSS J. 2009 Sep;5(2):123-8
pubmed: 19590926
Clin Orthop Relat Res. 2005 Sep;438:116-22
pubmed: 16131879
J Bone Joint Surg Am. 2018 Mar 21;100(6):496-504
pubmed: 29557866
Acta Orthop. 2008 Feb;79(1):86-93
pubmed: 18283578
J Surg Oncol. 2019 Jun;119(7):864-872
pubmed: 30734307
Bone Joint J. 2014 Jan;96-B(1):127-31
pubmed: 24395323
Clin Orthop Relat Res. 2011 Apr;469(4):1181-7
pubmed: 20857250
Clin Orthop Relat Res. 2017 Mar;475(3):776-783
pubmed: 26932739
Clin Orthop Relat Res. 2005 Jun;(435):211-8
pubmed: 15930941
J Bone Joint Surg Am. 2012 Mar 7;94(5):461-7
pubmed: 22398741
Clin Orthop Relat Res. 2007 Jun;459:96-104
pubmed: 17417093
Int Orthop. 2006 Dec;30(6):490-4
pubmed: 16736146
Oncologist. 2014 May;19(5):550-61
pubmed: 24718514
Bone Joint J. 2015 Nov;97-B(11):1566-71
pubmed: 26530662
Int Orthop. 2004 Aug;28(4):239-43
pubmed: 15160253
Clin Orthop Relat Res. 2011 Nov;469(11):3200-8
pubmed: 21732023
J Bone Joint Surg Br. 2004 Mar;86(2):212-6
pubmed: 15046435
Int Orthop. 2017 Nov;41(11):2397-2400
pubmed: 28646421
J Bone Joint Surg Am. 2008 May;90(5):1060-7
pubmed: 18451399
Clin Orthop Relat Res. 2005 Sep;438:123-7
pubmed: 16131880
World J Surg Oncol. 2013 Jul 16;11:156
pubmed: 23866921
J Bone Joint Surg Br. 2007 Mar;89(3):361-5
pubmed: 17356150
Eur J Cancer. 2016 May;59:1-12
pubmed: 26990281
J Bone Joint Surg Br. 2011 Dec;93(12):1665-9
pubmed: 22161931
Iowa Orthop J. 2006;26:69-76
pubmed: 16789453
Clin Orthop Relat Res. 2002 Jul;(400):201-10
pubmed: 12072763
Acta Orthop. 2012 Aug;83(4):401-5
pubmed: 22880716
Eur J Surg Oncol. 2001 Mar;27(2):200-2
pubmed: 11289759
Clin Orthop Relat Res. 2004 Jul;(424):221-6
pubmed: 15241169
Sarcoma. 2010;2010:null
pubmed: 20706639
Musculoskelet Surg. 2016 Aug;100(2):149-56
pubmed: 27324025
J Cancer Res Clin Oncol. 2008 Sep;134(9):969-78
pubmed: 18322700
Eur J Orthop Surg Traumatol. 2017 Aug;27(6):813-819
pubmed: 28589498
Orthopedics. 2009 Jul;32(7):491
pubmed: 19634852
Clin Orthop Relat Res. 2009 May;467(5):1355-9
pubmed: 18987923
Cancer Treat Rev. 2010 Feb;36(1):1-7
pubmed: 19879054